Circulating lipocalin‐2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic stroke
Open Access
- 27 March 2023
- journal article
- research article
- Published by Wiley in Brain and Behavior
- Vol. 13 (5)
Abstract
Introduction: Lipocalin‐2 (LCN2) is an acute‐phase protein that could mediate neuroinflammation after brain injury. We aimed to evaluate if LCN2 level was associated with early neurological deterioration (END) in acute ischemic stroke patients, thus hindering clinical recovery.Methods: We conducted a prospective study of acute ischemic stroke patients between June 2021 and February 2022. Serum LCN2 concentration was measured after admission using an enzyme‐linked immunosorbent assay. Outcomes included END and 90‐day poor functional outcome (modified Rankin Scale 3‐6). The National Institutes of Health Stroke Scale increment ≥4 points within 72 h after admission was defined as END.Results: A total of 253 acute ischemic stroke patients (mean age, 65.2 ± 13.4 years; 64.0% male) were recruited. In the multivariate adjustment, increased serum LCN2 levels (per 1‐SD increase of LCN2) were associated with a higher risk of END (odds ratio [OR], 1.64; 95% confidence interval [CI], 1.20–2.25; p = .002) and 90‐day poor outcome (OR, 1.73; 95% CI, 1.22–2.45; p = .002). Restricted cubic splines found a linear relationship between LCN2 level and 90‐day unfavorable outcome (END, p = .001 for linearity; 90‐day poor outcome, p = .013 for linearity). Subgroup analysis further confirmed the significant association of LCN2 with clinical outcomes.Conclusions: This study demonstrated that higher circulating LCN2 level was associated with an increased risk of early clinical worsening and 90‐day unfavorable outcomes in ischemic stroke patients.Keywords
Funding Information
- National Natural Science Foundation of China (82171331)
- Natural Science Foundation of Jiangsu Province (BK20221553)
This publication has 34 references indexed in Scilit:
- Early Neurological Deterioration within 24 Hours after Intravenous rt-PA Therapy for Stroke Patients: The Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA RegistryCerebrovascular Diseases, 2012
- Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's diseaseThe FASEB Journal, 2012
- Early Neurological Deterioration (END) after Stroke: The END Depends on the DefinitionInternational Journal of Stroke, 2011
- Hemodynamic Factors and Perfusion Abnormalities in Early Neurological DeteriorationStroke, 2009
- Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and managementPostgraduate Medical Journal, 2008
- Expression of Neutrophil Gelatinase–Associated Lipocalin in Atherosclerosis and Myocardial InfarctionArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- A Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron UptakeCell, 2005
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989
- Flexible regression models with cubic splinesStatistics in Medicine, 1989